Drug news

Kamada files MAA at EMA for inhaled alpha-1 antitrypsin (AAT) therapy.

Read time: 1 mins

Last updated:11th Apr 2016

Published:11th Apr 2016

Source: Pharmawand

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the Company�s proprietary, inhaled alpha-1 antitrypsin (AAT) therapy as a treatment for AAT deficiency (AATD). The filing was validated by the EMA.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news